The access issues that are hampering sales growth for AstraZeneca PLC's Evusheld, are firmly in the spotlight again with the UK government's decision not to buy the antibody cocktail for the prevention of COVID-19 being described as irrenponsible and nonsense.
Evusheld (tixagevimab/cilgavimab) has full approval in the EU and received conditional marketing authorization in March across the Channel from the...